Clinical trials: Melanoma of Skin
Malignant Melanoma
Reducing Symptom Burden Through Physical Exercise in Melanoma Patients
The aim of the clinical trial is to determine whether regular exercise can reduce fatigue in adult patients with stage IIb-IV melanoma undergoing immunotherapy or targeted therapy.
- Trial name
- RESPECT (NCT06985056)
- Testing
- Supervised 12-week Resistance and Endurance Exercise Program
- Where
- Germany
- Volunteers
- 86 people
- Sponsor
- Universität Duisburg-Essen
Melanoma
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
Recent studies suggest that patients with metastatic melanoma whose gut microbiome is colonized by eubiotic bacteria have a stronger anti-cancer response to anti CTLA-4 and anti PD1.
- Trial name
- PICASSO (NCT04988841)
- Testing
- MaaT013, Ipilimumab, Nivolumab
- Where
- 5 sites in France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HLA-A2 Positive Cells Present, Refractory Melanoma
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to…
- Trial name
- NCT04093323
- Testing
- Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Melanoma
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
The purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines (ipilimumab and nivolumab) given for the treatment of melanoma.
- Trial name
- PORTSIDE (NCT05926960)
- Testing
- encorafenib, binimetinib, pembrolizumab
- Where
- 24 sites in Germany, Italy and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Melanoma, Genetic Polymorphism
Multicentric Cohort of Melanoma Patients in Ile de France Area
This is a multicentric prospective cohort of all stage melanoma patients from AP-HP ,the largest consortium of University hospitals over Europe.
- Trial name
- Melan-Cohort (NCT00839410)
- Where
- France
- Volunteers
- 1,255 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-melanomatous Skin Cancer
Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with nonmelanoma skin cancer that has been treated with topical aminolevulinic acid may help doctors predict how patients will respond to photodynamic…
- Trial name
- NCT00663910
- Testing
- Aminolevulinic Acid, biopsy, diagnostic imaging technique
- Volunteers
- 18 people
- Sponsor
- The Cleveland Clinic
Malignant Melanoma
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with vemurafenib or vemurafenib plus cobimetinib in…
- Trial name
- NCT01656642
- Testing
- Atezolizumab, Cobimetinib, Vemurafenib
- Where
- 8 sites in United States
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Metastatic Melanoma, Skin Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving…
- Trial name
- NCT01468818
- Testing
- Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin
Intratumoral PH-762 for Cutaneous Carcinoma
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the…
- Conditions
- Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
- Trial name
- NCT06014086
- Testing
- PH-762
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Phio Pharmaceuticals Inc.
Stage IIA Skin Melanoma, Stage IIB Skin Melanoma
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
This randomized pilot clinical trial studies melanoma antigen recognized by T-cells 1 (MART-1) antigen with or without toll-like receptor 4 (TLR4) agonist glucopyranosyl lipid A-stable oil-in-water emulsion (GLA-SE) in treating…
- Conditions
- Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT02320305
- Testing
- MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Melanoma
Phase I trial to study the effectiveness of vaccine therapy in treating patients with melanoma that cannot be treated with surgery. Vaccines may make the body build an immune response that may kill tumor cells.
- Trial name
- NCT00003556
- Testing
- ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Breast Cancer
Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy
Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and systemic antitumoral immune responses.
- Conditions
- Prostate Cancer, Breast Cancer, Lung Cancer, Melanoma
- Trial name
- SBRT (NCT01777802)
- Testing
- SBRT, IMRT, Brachytherapy
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma.
- Trial name
- NCT04674683
- Testing
- HBI-8000 in combination with nivolumab
- Where
- 139 sites in United States, Australia and 15 more
- Volunteers
- 450 people
- Sponsor
- HUYABIO International, LLC.
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma that has not responded to…
- Trial name
- NCT00019994
- Testing
- MART-1 antigen, aldesleukin, gp100 antigen
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma, TOR Serine-Threonine Kinases
Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study
This is a single-armed, open-labeled and single-centered study of everolimus in selective patients with metastatic melanoma for evaluation of the efficacy and safety.
- Conditions
- Melanoma, TOR Serine-Threonine Kinases, Neoplasm Metastasis
- Trial name
- NCT01960829
- Testing
- Everolimus
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma
Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma
Rationale: Ipilimumab, a monoclonal antibody targeting CTLA-4, is approved for the treatment of metastatic melanoma and significantly increases median overall survival.
- Trial name
- Zirconipi (NCT03313323)
- Testing
- 89Zirconium-labeled ipilimumab
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Amsterdam UMC, location VUmc
Melanoma (Skin)
Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00085462
- Testing
- aldesleukin, filgrastim, gp100-fowlpox vaccine
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Melanoma, Metastatic Melanoma
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
This research study is studying the drugs called NeoVax (a new type of personalized neoantigen vaccine) in combination with CDX-301 and Nivolumab or Pembrolizumab as a possible treatment for melanoma.
- Trial name
- NCT04930783
- Testing
- CDX-301, NEOVAX, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Melanoma, Unresectable Melanoma
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
The purpose of this first in human study is to evaluate the feasibility, safety, and efficacy of administering TBio-4101 (tumor infiltrating lymphocytes [TIL]) after receiving a lymphodepleting chemotherapy regimen and before…
- Conditions
- Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma
- Trial name
- NCT05628883
- Testing
- TBio-4101, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.